Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Conjugated vaccines].

Bernard Fritzell1

  • 1International Scientific & Clinical Affairs, Wyeth Vaccines, La Défense, Paris, France. fritzeb@wyeth.com

Therapie
|September 1, 2005
PubMed
Summary
This summary is machine-generated.

Conjugate vaccines protect infants from encapsulated bacterial pathogens like Hib and pneumococcus by converting T-independent antigens into T-dependent ones, significantly reducing invasive diseases and providing herd protection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting.

EBioMedicine·2025
Same author

The TB vaccine development pathway - An innovative approach to accelerating global TB vaccine development.

Tuberculosis (Edinburgh, Scotland)·2020
Same author

Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations.

Vaccine·2019
Same author

Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.

The Lancet. Respiratory medicine·2019
Same author

Human challenge trials in vaccine development: Strasbourg, September 29 - October 1, 2014.

Biologicals : journal of the International Association of Biological Standardization·2015
Same author

Predictive markers of safety and immunogenicity of adjuvanted vaccines.

Biologicals : journal of the International Association of Biological Standardization·2013
Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026
Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026
Same journal

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge.

Therapie·2026
Same journal

Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.

Therapie·2026
Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026
See all related articles

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Context:

  • Infants and young children are vulnerable to encapsulated bacterial pathogens due to waning maternal antibodies and immature immune systems.
  • Polysaccharide capsules of bacteria like Haemophilus influenzae type b (Hib), Neisseria meningitidis, and Streptococcus pneumoniae are T-independent antigens, poorly immunogenic in young children.

Purpose:

  • To explain the mechanism of polysaccharide-protein conjugate vaccines in overcoming the immunodeficiency in infants against encapsulated bacteria.
  • To highlight the public health impact of conjugate vaccines in reducing invasive bacterial diseases.

Summary:

  • Conjugate vaccines convert bacterial polysaccharide antigens into T-dependent antigens by linking them to carrier proteins.
  • This conversion enables infants to mount a robust T-cell dependent immune response, leading to protective immunity.

Related Experiment Videos

  • Vaccination with conjugate vaccines has dramatically reduced the incidence of invasive diseases caused by Hib, meningococcus, and pneumococcus.

    • Impact:

    • Conjugate vaccines have led to an over 80% reduction in invasive diseases caused by targeted pathogens, representing a major public health achievement.
    • These vaccines confer 'herd protection' by reducing nasopharyngeal colonization in vaccinated children, thereby protecting unvaccinated individuals.
    • Future research focuses on expanding the serogroups targeted by meningococcal and pneumococcal conjugate vaccines to broaden protection.